Selected article for: "activity sars and lopinavir ritonavir"
Author: Zhichao Feng; Jennifer Li; Shanhu Yao; Qizhi Yu; Wenming Zhou; Xiaowen Mao; Huiling Li; Wendi Kang; Xin Ouyang; Ji Mei; Qiuhua Zeng; Jincai Liu; Xiaoqian Ma; Pengfei Rong; Wei Wang
Title: The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis
  • Document date: 2020_4_10
    • ID: k65501xp_6
    Snippet: While there is no specific therapy for COVID-19, current progress with investigational therapies includes the development and trial of a coronavirus vaccine and interrogation of several orphan drugs in randomized control trials (RCTs). 7 This includes remdesivir, which has garnered the most interest in an ongoing adaptive RCT and other nucleotide analogues including ritonavir, favipiravir and galidesvir. 8 A recently published open-label RCT show.....
    Document: While there is no specific therapy for COVID-19, current progress with investigational therapies includes the development and trial of a coronavirus vaccine and interrogation of several orphan drugs in randomized control trials (RCTs). 7 This includes remdesivir, which has garnered the most interest in an ongoing adaptive RCT and other nucleotide analogues including ritonavir, favipiravir and galidesvir. 8 A recently published open-label RCT showed no benefit of the protease inhibitors lopinavir/ritonavir in reducing clinical severity or mortality associated with COVID-19, despite in vitro evidence of activity against SARS-CoV-2. 9 Other drugs of interest include antiviral therapy (pegylated interferon-alpha, arbidol) and immunomodulators (hydroxychloroquine) are also under investigation and results are eagerly monitored. 10, 11 . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • antiviral therapy and clinical severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antiviral therapy and control trial: 1, 2
    • antiviral therapy and coronavirus vaccine: 1, 2
    • antiviral therapy and current progress: 1, 2
    • antiviral therapy and interest drug: 1
    • antiviral therapy and interferon alpha: 1, 2, 3, 4, 5, 6, 7
    • antiviral therapy and International license: 1, 2, 3, 4, 5, 6, 7, 8
    • antiviral therapy and investigational therapy: 1, 2, 3
    • antiviral therapy and mortality clinical severity: 1, 2
    • cc NC ND International license and clinical severity: 1, 2, 3, 4
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and nucleotide analogue: 1, 2, 3, 4
    • clinical severity and control trial: 1, 2, 3
    • clinical severity and coronavirus vaccine: 1, 2
    • clinical severity and interest drug: 1
    • clinical severity and interferon alpha: 1, 2, 3
    • clinical severity and International license: 1, 2, 3, 4, 5, 6
    • clinical severity and mortality clinical severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • control trial and investigational therapy: 1, 2